ProS1

ProS1 Molekülinformation

Englischer Name	Prostate-specific antigen	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	2	Target-Alias	P-30 antigen，Semenogelase，APS，Prostate-specific antigen，PSA，Kallikrein Related Peptidase 3，Gamma-Seminoprotein，Kallikrein-3，Seminin，Kallikrein 3， (Prostate Specific Antigen)，EC 3.4.21.77，KLK2A1，HK3，KLK3，EC 3.4.21，EC:3.4.21.77
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Prostate-specific antigen
Target-Alias	P-30 antigen，Semenogelase，APS，Prostate-specific antigen，PSA，Kallikrein Related Peptidase 3，Gamma-Seminoprotein，Kallikrein-3，Seminin，Kallikrein 3， (Prostate Specific Antigen)，EC 3.4.21.77，KLK2A1，HK3，KLK3，EC 3.4.21，EC:3.4.21.77
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	2
Höchste Forschungs- und Entwicklungsphase	Approved

ProS1 Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
PR1-H52H3	Human	HEK293	Human ProS1 Protein, His Tag				In den Warenkorb legen

Gesamtmenge1

ProS1 Molekülhintergrund

This gene is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The encoded protein belongs to the subfamily B class of LIR receptors which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

ProS1 Molekülalias

PROS, PS21, PS22, PS23, PS24, PS25, PSA, THPH5, THPH6

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Tb161-RAD402	Tb161-RAD402	Phase 2 Clinical	Radiopharm Theranostics Ltd	Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant	Details
GEA-408	GEA-408	Phase 2 Clinical	GenEros Biopharma Hangzhou Ltd	Prostatic Neoplasms	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Afala		Approved	Materia Medica Holding Research And Production Company		Russian Federation	Prostatic Neoplasms; Prostatitis	Materia Medica Holding Research And Production Company	2014-01-01	Prostatic Neoplasms; Prostatitis	Details